Intismeran Autogene Phase 3 Win: First-Mover Validated, But Magnitude Unknown

Moderna's Stock Skyrockets Over 600% on Melanoma Vaccine Success

Moderna has experienced a significant turnaround in 2026, with its shares climbing over 600% this year, vastly outperforming the biotech index fund (XBI) which gained 23%. This surge follows a period of decline after the COVID-19 pandemic. A key driver for this recovery was the Phase 3 success in August of intismeran autogene, a melanoma vaccine co-developed with Merck & Co., which analysts hailed as a “landmark moment” and “major win” expected to unlock billions in future sales. The market is now keenly awaiting the presentation of these study details at an upcoming medical meeting.

• After a period of financial struggles and plummeting demand for its COVID-19 vaccine, Moderna's shares have surged by over 600% in 2026, significantly outpacing the 23% gains of the broader biotech index fund (XBI). This remarkable stock recovery has brought the company closer to its pandemic-era valuation highs.
• The August Phase 3 success of intismeran autogene, a melanoma vaccine co-developed with Merck & Co., was a pivotal event. Analysts from Raymond James described it as the "clearest example of how aggressively investors will reward meaningful clinical de-risking," indicating its substantial impact on investor confidence and future sales potential.
• The market is highly anticipating the presentation of the intismeran autogene study results at a medical meeting later this month. RBC Capital Markets analyst Trung Huynh highlighted this event as "likely the biggest event" for both Moderna and Merck for the remainder of the year, suggesting its critical importance for continued stock performance and strategic direction.

Addressing Unmet Needs in Melanoma with Intismeran Autogene

Despite meaningful advances in immune checkpoint inhibition and targeted therapy, substantial unmet needs persist across multiple melanoma populations. Patients who progress on or are refractory to anti-PD-1 therapy, those with rare histologic subtypes, and heavily pretreated individuals with high disease burden represent the most critically underserved groups driving current clinical and translational research.

• ICI-refractory and heavily pretreated advanced melanoma: Patients with advanced melanoma resistant to immune checkpoint inhibitors (ICIs) or BRAF/MEK inhibitors have treatment options with relatively low efficacy. This population has been a primary target for tumor-infiltrating lymphocyte (TIL) therapy, with lifileucel approved by the US FDA based on the pivotal C-144-01 study. At 5-year follow-up, the objective response rate was 31.4% (complete response 5.9%; partial response 25.5%), median overall survival was 13.9 months, and 5-year OS was 19.7%. Real-world data across multiple US centers showed a physician-assessed ORR of 44% among 41 response-evaluable patients, with ORR of 52% among patients who received ≤2 prior lines of therapy versus 33% among those who received ≥3 prior lines, underscoring the benefit of earlier TIL therapy consideration.

• Rare and aggressive melanoma subtypes — acral, mucosal, and uveal: Rare histologic subtypes, including acral, mucosal, and uveal melanomas, make up only 5% of all diagnosed melanomas and are frequently underrepresented in large randomized trials. Acral melanoma has a poor response to immunotherapy and is associated with worse survival. Mucosal melanoma carries a large variability in presentation, poor prognosis, low mutational burden, and resistance to traditional ICIs, accounting for 1%–2% of new cases in the United States and 20%–30% in China and other Asian countries. Uveal melanoma is associated with a high rate of liver metastasis and poor overall prognosis, with metastatic overall survival ranging from 3 to 30 months; tebentafusp has shown an overall survival benefit specifically in HLA-A*02:01-positive patients, representing the first anti-cancer treatment to demonstrate an OS benefit in this population.

• Patients with high-risk features limiting standard treatment delivery: High-risk metastatic melanoma patients — including those aged ≥70 years, with recently treated brain metastases, bowel metastases, bleeding, or requiring continuous antiplatelet or anticoagulation use — have historically been excluded from or poorly served by standard TIL therapy protocols due to toxicity from high-intensity lymphodepleting conditioning. Reduced-dose lymphodepletion (cyclophosphamide 30 mg/kg daily for 2 days) followed by lifileucel has been investigated in this cohort, with a partial response rate of 44% among 16 evaluable patients and no deaths within 30 days of TIL infusion, demonstrating feasibility without an obvious detrimental effect on response rate.

• Optimizing neoadjuvant and adjuvant strategies for resectable high-risk melanoma: For patients with resectable stage III/IV melanoma, there remains an unmet need to identify biomarkers predicting response and to define optimal perioperative immunotherapy sequencing. A phase II trial of neoadjuvant nivolumab and relatlimab achieved a major pathologic response (MPR; ≤10% viable tumor) rate of 63%, with 80% of patients remaining event-free at 4 years from the start of neoadjuvant systemic treatment, and 95% of MPR patients remaining event-free. Baseline upregulation of immune modulatory pathways was associated with MPR, while increased B7-H3 expression was associated with resistance, identifying a potentially targetable predictor.

• Sequencing and resistance to combination ICI regimens: A critical lack of robust data exists to determine optimal sequencing of ICI combinations. A multicenter study of 190 patients evaluating relatlimab plus nivolumab (rela/nivo) within treatment sequences found that median OS from first ICI treatment was 40.9 months in patients receiving ipilimumab plus nivolumab followed by rela/nivo, and 42.5 months in patients receiving anti-PD-1 followed by rela/nivo, compared with 16.3 months in patients receiving rela/nivo first. Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, highlighting the need for sequencing strategies informed by prior response patterns.

• BRAF/NRAS wild-type melanoma post-ICI progression: Patients with BRAF/NRAS wild-type melanoma who progress after ICIs have a poor prognosis with limited targeted options. A phase II trial of trametinib plus low-dose dabrafenib in this population demonstrated a confirmed objective response rate of 29.2%, median progression-free survival of 13.3 weeks (95% CI, 3.5 to 23.1), and median overall survival of 54.3 weeks (95% CI, 37.9 to 70.6), with MAPK pathway-activating alterations identified as a promising predictive biomarker and a disease control rate of 64.3% in that subgroup.

Key Efficacy and Safety Outcomes of Intismeran Autogene in Melanoma

Recent clinical investigations across multiple settings have advanced the understanding of immune checkpoint inhibitors and novel combination regimens in melanoma, spanning first-line, second-line, and refractory populations. The studies below highlight key efficacy and safety findings from trials evaluating both established and emerging therapeutic strategies.

• KEYNOTE-029 Part 1B (pembrolizumab 200 mg every 3 weeks + ipilimumab 1 mg/kg every 3 weeks for four cycles, then pembrolizumab alone): At a median follow-up of 36.8 months, the objective response rate (ORR) was 62.1%, comprising 27.5% complete responses and 34.6% partial responses. Median duration of response (DOR) was not reached, with a 36-month ongoing response rate of 84.2%. Median progression-free survival (PFS) and overall survival (OS) were not reached; 36-month rates were 59.1% and 73.4%, respectively. Treatment-related adverse events (TRAEs) occurred in 96.1% of patients (47.1% grade 3/4; no deaths), with discontinuation of one or both drugs in 35.9%.

• KEYNOTE-151 (pembrolizumab 2 mg/kg every 3 weeks, second-line, Chinese patients): In 103 patients with a median follow-up of 7.9 months, ORR was 16.7% (95% CI, 10.0–25.3%), with 1 complete and 16 partial responses. Disease control rate was 38.2%. Median DOR was 8.4 months; 65.6% of patients had response duration ≥6 months. Median PFS was 2.8 months (95% CI, 2.7–3.5 months); median OS was 12.1 months (95% CI, 9.6 months–not reached). TRAEs occurred in 84.5% of patients; grade 3/4 TRAEs in 8.7%; 1.9% discontinued due to TRAEs; no treatment-related deaths.

• MASTERKEY-115 (talimogene laherparepvec + pembrolizumab, anti-PD-1–refractory advanced melanoma): Among 71 treated patients across four cohorts, ORR per RECIST v1.1 was 0%, 6.7%, 40.0%, and 46.7% in cohorts 1–4, respectively. Immune-confirmed ORR (iORR) was 3.8%, 6.7%, 53.3%, and 46.7%. Median iPFS was 5.5, 8.2, not estimable, and not estimable months for cohorts 1–4. TRAEs occurred in 76.1% of patients; grade ≥3 TRAEs in 12.7%; serious AEs in 33.8%; fatal AEs in 14.1%.

• Nivolumab-relatlimab real-world study (first-line, multicenter retrospective, Israel): In 117 patients (median age 75 years; 38% aged ≥80 years), ORR was 69.8%, including a complete response rate of 43.6%. Median PFS was 18.6 months; median OS and melanoma-specific survival were not reached; 12-month OS was 74.1%. Grade 3–4 adverse events occurred in 11% of patients; treatment discontinuation due to toxicity in 14.5%, predominantly among patients aged ≥80 years. A higher-than-anticipated rate of neurologic toxicity was observed.

• Atezolizumab + bevacizumab phase II study (first-line advanced mucosal melanoma): Among 40 response-evaluable patients (median follow-up 13.4 months), ORR was 45.0% (95% CI, 29.3%–61.5%; 1 complete response, 17 partial responses). Median PFS was 8.2 months (95% CI, 2.7–9.6); median OS was not reached (95% CI, 14.4–NR). Median DOR was 12.5 months (95% CI, 5.5–NR). TRAEs occurred in 90.7% of patients; grade ≥3 events in 25.6%.

Intismeran Autogene's Position in the Melanoma Vaccine Landscape

The knowledge base does not have sufficient information to answer this question.

Personalized mRNA Vaccine: A New Frontier in Adjuvant Melanoma

The recent announcement of a successful Phase 3 trial for intismeran autogene (mRNA-4157/V940) in combination with pembrolizumab marks a potentially transformative moment in the treatment of high-risk resected melanoma. For years, immune checkpoint inhibitors like pembrolizumab have significantly improved outcomes, offering patients with stage IIB, IIC, and III melanoma a better chance at recurrence-free survival and distant metastasis-free survival. However, a notable proportion still face recurrence, underscoring the ongoing need for more potent and precise therapeutic options.

This new combination therapy, co-developed by Moderna and Merck, represents a significant leap forward by introducing an individualized neoantigen vaccine. Unlike broad immunotherapies, mRNA-4157 is designed to target up to 34 patient-specific tumor neoantigens, aiming to induce highly specific T-cell responses. Early phase studies have shown this approach can generate de novo and strengthen existing neoantigen-specific T-cell responses, providing a mechanistic rationale for enhanced anti-tumor activity when combined with PD-1 blockade. This personalized strategy stands in contrast to other combination attempts in adjuvant melanoma that have failed to show additional benefit over monotherapy, highlighting the unique promise of mRNA-based neoantigen vaccines.

The strategic implications are profound. For Moderna, it validates their mRNA platform's versatility beyond infectious diseases, positioning them as a key player in oncology. For the broader melanoma community, it could establish a new benchmark for adjuvant care, pushing the boundaries of personalized medicine. However, several considerations remain. The full Phase 3 data will be crucial to confirm the magnitude and statistical significance of the benefit, especially given the borderline p-value in earlier studies. Furthermore, while generally manageable, the combination therapy did show a higher rate of grade ≥3 adverse events, necessitating careful long-term safety monitoring. Finally, the logistical and cost implications of manufacturing an individualized therapy for a broad patient population will be a critical factor in its real-world accessibility and integration into clinical practice. This development signals a future where precision medicine, tailored to each patient's unique tumor, could become a cornerstone of cancer treatment.